SCHEMBL853933

SCHEMBL853933

COCC(=O)Nc1ccc(N)cc1

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
ALDH1A1 P00352 3/20 0.69
MAPT P10636 3/20 0.65
ALOX12 P18054 1/20 0.65
MAPK1 P28482 1/20 0.65
HTT P42858 1/20 0.65
RAB9A P51151 3/20 0.59
CYP2C19 P33261 1/20 0.56
NPC1 O15118 1/20 0.55
KDM4C Q9H3R0 1/20 0.54
MTNR1A P48039 1/20 0.54
MTNR1B P49286 1/20 0.54
KDM4E B2RXH2 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KMT2A Q03164 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14962804 0.90 HPGD (0.81) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL7845225 0.88 HPGD (0.56) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL1976948 0.83 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL22854085 0.83 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL764569 0.83 HPGD (0.71) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL178376 0.82 HPGD (1.00) HPGDSMN1; SMN2ALDH1A1MAPTALOX12
SCHEMBL11727915 0.82 ALDH1A1 (0.63) HPGDSMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL3037762 0.82 L3MBTL1 (0.51) HPGDSMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL10238819 0.82 ALDH1A1 (0.71) HPGDSMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL5347276 0.81 RAB9A (0.53) HPGDSMN1; SMN2ALDH1A1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-05-11 US disclosed
EP-4161930-A1 NOVEL IMIDAZO-PYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2023-04-12 EP disclosed
CN-115667264-A Novel imidazo-pyrazine derivatives 豪夫迈·罗氏有限公司 2023-01-31 CN disclosed
WO-2021249893-A1 NOVEL IMIDAZO-PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2021-12-16 WO disclosed
CN-108530444-B Novel NAMPT and IDO dual inhibitor and preparation method and medical application thereof 药康众拓(江苏)医药科技有限公司 2021-08-24 CN disclosed
EP-3008045-B1 ANTIBACTERIAL THIAZOLECARBOXYLIC ACIDS ANTABIO SAS (FR) 2018-05-09 EP disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-8901315-B2 Thienopyrazole derivative having PDE7 inhibitory activity DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-12-02 US disclosed
US-8802448-B2 Mixed mode ligands PALL CORPORATION (US) 2014-08-12 US disclosed
WO-2000018734-A1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-04-06 WO disclosed
EP-0922034-A1 TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS GLAXO WELLCOME S.p.A. (IT) 1999-06-16 EP disclosed
WO-1998007704-A1 TETRAHYDROQUINOLINE DERIVATIVES AS EAA ANTAGONISTS GLAXO WELLCOME S.P.A. (IT) 1998-02-26 WO disclosed
US-4742160-A CATIONIC DYES; PRINTING SANDOZ LTD. (CH) 1988-05-03 US disclosed
EP-0087706-B1 CATIONIC HYDRAZONE DYES, THEIR MANUFACTURE AND THEIR USE BAYER AG (DE) 1986-07-30 EP disclosed
US-4496719-A 3H-Indol-2-yl cationic hydrazone dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1985-01-29 US disclosed
EP-0087706-A2 Cationic hydrazone dyes, their manufacture and their use BAYER AG (DE) 1983-09-07 EP disclosed
US-4224448-A FUNGICIDES, BACTERICIDES HABER RAPHAEL R G 1980-09-23 US disclosed
US-4220586-A FASTNESS TO LIGHT, OVER-LACQUERING, MIGRATION, WEATHERING, AND HEAT CIBA-GEIGY CORPORATION (US) 1980-09-02 US disclosed
US-4080321-A COLORFASTNESS HOECHST AKTIENGESELLSCHAFT (DT) 1978-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230141403-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES XDH, MYD88, IKZF3 HPGD 1801/4885SMN1; SMN2 2032/4885ALDH1A1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.